BIOMAT Database Logo BIOMAT Database Logo

Hepatitis A virus antibodies in immunoglobulin preparations. 2010

Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
Global Pathogen Safety, Baxter BioScience, Vienna, Austria.

BACKGROUND Persons with primary immune deficiency receive intravenous immunoglobulin (IVIG) as antibody replacement therapy. These patients depend on the presence of protective antibody levels against circulating pathogens in IVIG. OBJECTIVE The incidence of hepatitis A virus (HAV) infections has been decreasing globally. We investigated whether this decrease in HAV incidence is reflected in human plasma pools and evaluated whether HAV antibody titers in IVIG preparations are still adequate for antibody replacement. METHODS By using ELISA, the HAV antibody titer of 3,953 plasma pools sourced from March 2003 through September 2008 in the European Union (EU) or United States (US) and of 169 IVIG lots manufactured from 2005 through 2007 was determined. The functionality of the HAV antibodies contained in IVIG was assessed by using a microneutralization assay. RESULTS The results confirm a decrease in HAV antibody titers in EU (-28%) and US (-41%) plasma. Furthermore, the mean HAV antibody content in EU (1.70 +/- 0.12 IU/mL) and US (0.82 +/- 0.09 IU/mL [mean +/- SEM]) plasma was significantly different (P = .0001). A significant difference (P < .0001) was also evident in the IVIG preparations KIOVIG (22.91 +/- 0.68 IU/mL) and Gammagard Liquid (14.60 +/- 0.48 IU/mL), respectively, made from EU or US plasma. In accordance with the ELISA results, there was a significant difference (P < .0001) in HAV neutralization titer 50% (NT(50)) values between IVIG produced from EU-sourced (2,477 +/- 265 NT(50) [1:X]) or US-sourced (844 +/- 82 NT(50) [1:X]) plasma. CONCLUSIONS Although HAV antibody seroprevalence continues to decrease in Europe and the US, HAV antibody titers in IVIG lots appear to remain adequate for antibody replacement therapy.

UI MeSH Term Description Entries
D007153 Immunologic Deficiency Syndromes Syndromes in which there is a deficiency or defect in the mechanisms of immunity, either cellular or humoral. Antibody Deficiency Syndrome,Deficiency Syndrome, Immunologic,Deficiency Syndromes, Antibody,Deficiency Syndromes, Immunologic,Immunologic Deficiency Syndrome,Immunological Deficiency Syndromes,Antibody Deficiency Syndromes,Deficiency Syndrome, Antibody,Deficiency Syndrome, Immunological,Deficiency Syndromes, Immunological,Immunological Deficiency Syndrome,Syndrome, Antibody Deficiency,Syndrome, Immunologic Deficiency,Syndrome, Immunological Deficiency,Syndromes, Antibody Deficiency,Syndromes, Immunologic Deficiency,Syndromes, Immunological Deficiency
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D005060 Europe The continent north of AFRICA, west of ASIA and east of the ATLANTIC OCEAN. Northern Europe,Southern Europe,Western Europe
D006506 Hepatitis A INFLAMMATION of the LIVER in humans caused by a member of the HEPATOVIRUS genus, HUMAN HEPATITIS A VIRUS. It can be transmitted through fecal contamination of food or water. Hepatitis, Infectious,Infectious Hepatitis,Hepatitides, Infectious,Infectious Hepatitides
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014481 United States A country in NORTH AMERICA between CANADA and MEXICO.
D015994 Incidence The number of new cases of a given disease during a given period in a specified population. It also is used for the rate at which new events occur in a defined population. It is differentiated from PREVALENCE, which refers to all cases in the population at a given time. Attack Rate,Cumulative Incidence,Incidence Proportion,Incidence Rate,Person-time Rate,Secondary Attack Rate,Attack Rate, Secondary,Attack Rates,Cumulative Incidences,Incidence Proportions,Incidence Rates,Incidence, Cumulative,Incidences,Person time Rate,Person-time Rates,Proportion, Incidence,Rate, Attack,Rate, Incidence,Rate, Person-time,Rate, Secondary Attack,Secondary Attack Rates
D015995 Prevalence The total number of cases of a given disease in a specified population at a designated time. It is differentiated from INCIDENCE, which refers to the number of new cases in the population at a given time. Period Prevalence,Point Prevalence,Period Prevalences,Point Prevalences,Prevalence, Period,Prevalence, Point,Prevalences
D016756 Immunoglobulins, Intravenous Immunoglobulin preparations used in intravenous infusion, containing primarily IMMUNOGLOBULIN G. They are used to treat a variety of diseases associated with decreased or abnormal immunoglobulin levels including pediatric AIDS; primary HYPERGAMMAGLOBULINEMIA; SCID; CYTOMEGALOVIRUS infections in transplant recipients, LYMPHOCYTIC LEUKEMIA, CHRONIC; Kawasaki syndrome, infection in neonates, and IDIOPATHIC THROMBOCYTOPENIC PURPURA. Antibodies, Intravenous,Human Intravenous Immunoglobulin,IV Immunoglobulin,IVIG,Intravenous Antibodies,Intravenous Immunoglobulin,Intravenous Immunoglobulins,Alphaglobin,Endobulin,Flebogamma DIF,Gamimmune,Gamimmune N,Gamimune,Gamimune N,Gammagard,Gammonativ,Gamunex,Globulin-N,IV Immunoglobulins,Immune Globulin Intravenous (Human),Immune Globulin, Intravenous,Immunoglobulins, Intravenous, Human,Intraglobin,Intraglobin F,Intravenous IG,Intravenous Immunoglobulins, Human,Iveegam,Modified Immune Globulin (Anti-Echovirus Antibody),Privigen,Sandoglobulin,Venimmune,Venoglobulin,Venoglobulin-I,Globulin N,Human Intravenous Immunoglobulins,Immunoglobulin, Human Intravenous,Immunoglobulin, IV,Immunoglobulin, Intravenous,Immunoglobulins, Human Intravenous,Immunoglobulins, IV,Intravenous Immune Globulin,Intravenous Immunoglobulin, Human,Venoglobulin I
D030041 Hepatitis A virus A species in the genus HEPATOVIRUS containing one serotype and two strains: HUMAN HEPATITIS A VIRUS and Simian hepatitis A virus causing hepatitis in humans (HEPATITIS A) and primates, respectively. Hepatitis A viruses

Related Publications

Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Hepatitis A virus antibodies in preparations of normal immunoglobulin of Polish production].
July 1980, Polski tygodnik lekarski (Warsaw, Poland : 1960),
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
Hepatitis A virus concentrations in immunoglobulin preparations.
February 1991, Lancet (London, England),
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
Hepatitis A virus, blood donors, and immunoglobulin preparations.
May 1991, Lancet (London, England),
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Quantitative evaluation of the content of antibodies to hepatitis of A virus in serial immunoglobulin preparations].
September 1982, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Prophylactic effectiveness of immunoglobulin preparations with different amounts of specific antibodies to the hepatitis A virus].
December 1988, Voenno-meditsinskii zhurnal,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Concentration of specific antibodies to hepatitis B antigen in immunoglobulin preparations].
February 1981, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
Antibodies against Hepatitis A and Hepatitis B Virus in Intravenous Immunoglobulin Products.
December 2016, Journal of Korean medical science,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Erythrocyte antibodies in immunoglobulin preparations].
May 1981, Blut,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
Lack of antibodies to the envelope glycoproteins of hepatitis C virus in immunoglobulin preparations from screened donors.
January 1996, Bollettino della Societa italiana di biologia sperimentale,
Maria R Farcet, and Christina B Planitzer, and Oliver Stein, and Jens Modrof, and Thomas R Kreil
[Effect of the content of hepatitis A antibodies in immunoglobulin preparations on the effectiveness of the immunoglobulin prophylaxis of hepatitis A].
June 1984, Zhurnal mikrobiologii, epidemiologii i immunobiologii,
Copied contents to your clipboard!